|
61 |
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin |
Ferrannini G, Gerstein H, Colhoun HM, Dagenais GR, Diaz R, Dyal L, Lakshmanan M, Mellbin L, Probstfield J, Riddle MC, Shaw JE, *Pais P*, et al.. |
Eur Heart J |
2020 |
|
62 |
Urinary Sodium and Potassium, and Risk of Ischaemic and Haemorrhagic Stroke (INTERSTROKE): a case-control study |
Judge C, O'Donnell MJ, Hankey GJ, Rangarajan S, Chin SL, Rao-Melacini P, Ferguson J, Smyth A, Xavier D, Lisheng L, Zhang H, Lopez-Jaramillo P, Damasceno A, Langhorne P, Rosengren A, Dans AL, Elsayed A, Avezum A, Mondo C, Ryglewicz D, Czlonkowska A, Pogosova N, Weimar C, Diaz R, Yusoff K, Yusufali A, Oguz A, Wang X, Lanas F, Ogah OS, Ogunniyi A, Iversen HK, Malaga G, Rumboldt Z, Oveisgharan S, Hussain FA, Yusuf S |
Am J Hypertens |
2020 |
|
63 |
Polypill with or without Aspirin in Persons without Cardiovascular Disease |
Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, López-Jaramillo P, Yusoff K, Santoso A, Gamra H, Talukder S, Christou C, Girish P, Yeates K, Xavier F, Dagenais G, Rocha C, McCready T, Tyrwhitt J, Bosch J, Pais P; International Polycap Study 3 Investigators |
N Engl J Med |
2020 |
|
64 |
Situational analysis of practice patterns and challenges in cardiovascular disease management: A qualitative study |
Farah Naaz Fathima, Twinkle Agrawal, Padmini Nidhin, *Denis Xavier* |
Int. J of Non communicable Diseases |
2020 |
|
65 |
Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation |
Anthony P Carnicelli, Sana M Al-Khatib, *Denis Xavier*, Frederik Dalgaard, Peter D Merrill, Daniel M Wojdyla, Basil S Lewis, Michael Hanna, John H Alexander, Renato D Lopes, Lars Wallentin, Christopher B Granger. |
Heart |
2020 |
|
66 |
Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial |
Washam JB, Hohnloser SH, Lopes RD, Wojdyla DM, Vinereanu D, Alexander JH, Gersh BJ, Hanna M, Horowitz J, Hylek EM, Xavier D, Verheugt FWA, Wallentin L, Granger CB; ARISTOTLE Committees and Investigators. |
J Thromb Thrombolysis |
2019 |
|
67 |
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial |
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. |
Lancet |
2019 |
|
68 |
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial |
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators |
Lancet |
2019 |
|
69 |
Association between complications and death within 30 days after noncardiac surgery |
Spence J, LeManach Y, Chan MTV, Wang CY, Sigamani A, Xavier D, Pearse R, Alonso-Coello P, Garutti I, Srinathan SK, Duceppe E, Walsh M, Borges FK, Malaga G, Abraham V, Faruqui A, Berwanger O, Biccard BM, Villar JC, Sessler DI, Kurz A, Chow CK, Polanczyk CA, Szczeklik W, Ackland G, Garg AX, Jacka M, Guyatt GH, Sapsford RJ, Williams C, Cortes OL, Coriat P, Patel A, Tiboni M, Belley-Côté EP, Yang S, Heels-Ansdell D, McGillion M, Schünemann HJ, Parlow S, Patel M, Pettit S, Yusuf S, Devereaux PJ; on behalf of the VISION Investigators |
CMAJ |
2019 |
|
70 |
Cardiovascular risk factor reduction by community health workers in rural India: A cluster randomized trial |
Joshi R, Agrawal T, Fathima F, Usha T, Thomas T, Misquith D, Kalantri S, Chidambaram N, Raj T, Singamani A, Hegde S, Xavier D, Devereaux PJ, Pais P, Gupta R, Yusuf S |
Am Heart J |
2019 |
|
71 |
Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights from the AUGUSTUS Trial |
Windecker S, Lopes RD, Massaro T, Jones-Burton C, Granger CB, Aronson R, Heizer G, Goodman SG, Darius H, Jones WS, Aschermann M, Brieger D, Cura F, Engstrøm T, Fridrich V, Halvorsen S, Huber K, Kang HJ, Leiva-Pons JL, Lewis BS, Malaga G, Meneveau N, Merkely B, Milicic D, Morais J, Potpara TS, Raev D, Sabaté M, de Waha-Thiele S, Welsh RC, Xavier D, Mehran R, Alexander JH; AUGUSTUS Investigators. |
Circulation |
2019 |
|
72 |
Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial |
Szarek M, Steg PG, DiCenso D, Bhatt DL, Bittner VA, Budaj A, Diaz R, Goodman SG, Gotcheva N, Jukema JW, Pordy R, Roe MT, Sourdille T, White HD, Xavier D, Zeiher AM, Schwartz GG |
Circ Cardiovasc Qual Outcomes |
2019 |
|
73 |
Prescription Pattern, Short-Term Outcomes, and Its Determinants in Patients With Chronic Kidney Disease Attending a Tertiary Care Hospital |
Mamadi RK, Sathish R, Selvaraj DR, Rathore R, Jose JV, Xavier D |
Indian J Pharmacol |
2019 |
|
74 |
Prescription Pattern, Short-Term Outcomes, and Its Determinants in Patients With Chronic Kidney Disease Attending a Tertiary Care Hospital |
Mamadi RK, Sathish R, Selvaraj DR, Rathore R, Jose JV, Xavier D |
Indian J Pharmacol |
2019 |
|
75 |
The impact of air pollution on deaths, disease burden, and life expectancy across the states of India: the Global Burden of Disease Study 2017. |
K Balakrishnan, S Dey, T Gupta, RS Dhaliwal, M Brauer, AJ Cohen, *D Xavier*, et al.. |
The Lancet Planetary Health |
2019 |